For Patients & General Readers

Systemic Lupus Erythematosus (SLE), often called lupus, is a chronic autoimmune disease where the body's immune system mistakenly attacks its own healthy tissues. It can affect many parts of the body, including the skin, joints, kidneys, brain, and blood. While there's no cure, effective treatments can help manage symptoms and prevent serious complications.

Clinical Overview

Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies, particularly antinuclear antibodies (ANAs), leading to immune complex deposition and inflammation in various organs. Its pathogenesis involves genetic predisposition, environmental triggers, and immune dysregulation, resulting in a highly variable clinical course.

Clinical Presentation

Fever
Fatigue
Arthralgias and arthritis
Cutaneous manifestations (e.g., malar rash, discoid lupus)
Serositis (pleuritis, pericarditis)
Renal involvement (lupus nephritis)
Neurologic symptoms (e.g., seizures, psychosis)
Hematologic abnormalities (e.g., anemia, thrombocytopenia, leukopenia)

Signs & Symptoms

Symptoms (Patient-Reported)

Extreme tiredness
Pain or swelling in the joints
Skin rashes, especially a butterfly-shaped rash across the cheeks and nose
Fever without a clear cause
Shortness of breath
Chest pain
Headaches
Memory problems

Signs (Clinician-Observed)

Malar rash (butterfly rash)
Discoid lupus lesions
Photosensitivity
Oral or nasal ulcers
Alopecia
Raynaud's phenomenon

Differential Diagnoses

Condition	Distinguishing Feature
Rheumatoid Arthritis	Primarily affects joints symmetrically with morning stiffness; less likely to have widespread organ involvement or characteristic lupus rashes.
Dermatomyositis	Characterized by heliotrope rash and Gottron's papules, with proximal muscle weakness being a prominent feature.
Sjogren's Syndrome	Primarily causes dryness of eyes and mouth; systemic features can overlap but are less common and severe than in SLE.
Mixed Connective Tissue Disease (MCTD)	Presents with overlapping features of SLE, scleroderma, and polymyositis; often has high titers of anti-U1-RNP antibodies.
Drug-Induced Lupus Erythematosus	Symptoms often resolve upon discontinuation of the offending drug; typically lacks central nervous system or renal involvement.
Sarcoidosis	Multisystem granulomatous disease; can mimic SLE with lung, skin, and joint involvement but typically has different serological markers.

Red Flags — Seek Immediate Care

Rapidly progressive glomerulonephritis (RPGN) or nephrotic syndrome
Seizures or psychosis in the setting of new-onset systemic illness
Severe hemolytic anemia or thrombocytopenia
Myocarditis or pericarditis with hemodynamic instability
Pulmonary hemorrhage

Key Investigations

Antinuclear Antibody (ANA) testing (highly sensitive, but not specific)
Anti-dsDNA and anti-Sm antibodies (highly specific for SLE)
Complement levels (C3, C4) (often low in active disease)
Complete Blood Count (CBC) with differential (to detect anemia, leukopenia, thrombocytopenia)
Urinalysis and urine protein-to-creatinine ratio (to assess renal involvement)
Renal biopsy (for definitive diagnosis and classification of lupus nephritis)
Imaging studies (e.g., chest X-ray, echocardiogram) as indicated by organ involvement

Management Overview

Management of SLE is individualized and aims to suppress the immune system, reduce inflammation, and prevent organ damage. Treatment strategies include pharmacologic interventions such as hydroxychloroquine, corticosteroids, immunosuppressants (e.g., azathioprine, mycophenolate mofetil, cyclophosphamide), and biologics (e.g., belimumab), alongside non-pharmacologic measures like sun protection and lifestyle modifications.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. TruelyserMD does not replace clinical judgement.